Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease

STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Prolifer...

Descripción completa

Detalles Bibliográficos
Autores principales: Re, D, Wickenhauser, C, Ahmadi, T, Buchdunger, E, Kochanek, M, Diehl, V, Wolf, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375346/
https://www.ncbi.nlm.nih.gov/pubmed/11953894
http://dx.doi.org/10.1038/sj.bjc.6600243
_version_ 1782154634811408384
author Re, D
Wickenhauser, C
Ahmadi, T
Buchdunger, E
Kochanek, M
Diehl, V
Wolf, J
author_facet Re, D
Wickenhauser, C
Ahmadi, T
Buchdunger, E
Kochanek, M
Diehl, V
Wolf, J
author_sort Re, D
collection PubMed
description STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571. British Journal of Cancer (2002) 86, 1333–1335. DOI: 10.1038/sj/bjc/6600243 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2375346
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23753462009-09-10 Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease Re, D Wickenhauser, C Ahmadi, T Buchdunger, E Kochanek, M Diehl, V Wolf, J Br J Cancer Experimental Therapeutics STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571. British Journal of Cancer (2002) 86, 1333–1335. DOI: 10.1038/sj/bjc/6600243 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-04-22 /pmc/articles/PMC2375346/ /pubmed/11953894 http://dx.doi.org/10.1038/sj.bjc.6600243 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Re, D
Wickenhauser, C
Ahmadi, T
Buchdunger, E
Kochanek, M
Diehl, V
Wolf, J
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title_full Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title_fullStr Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title_full_unstemmed Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title_short Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
title_sort preclinical evaluation of the antiproliferative potential of sti571 in hodgkin's disease
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375346/
https://www.ncbi.nlm.nih.gov/pubmed/11953894
http://dx.doi.org/10.1038/sj.bjc.6600243
work_keys_str_mv AT red preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT wickenhauserc preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT ahmadit preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT buchdungere preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT kochanekm preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT diehlv preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease
AT wolfj preclinicalevaluationoftheantiproliferativepotentialofsti571inhodgkinsdisease

Ejemplares similares